| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ... Journal of clinical oncology 24 (26), 4236-4244, 2006 | 850 | 2006 |
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 652 | 2011 |
| Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer A Tabchy, V Valero, T Vidaurre, A Lluch, H Gomez, M Martin, Y Qi, ... Clinical Cancer Research 16 (21), 5351-5361, 2010 | 228 | 2010 |
| Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers L Santarpia, Y Qi, K Stemke-Hale, B Wang, EJ Young, DJ Booser, ... Breast cancer research and treatment 134, 333-343, 2012 | 138 | 2012 |
| Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial A Obermair, R Asher, R Pareja, M Frumovitz, A Lopez, R Moretti-Marques, ... American journal of obstetrics and gynecology 222 (3), 249. e1-249. e10, 2020 | 116 | 2020 |
| El Instituto Nacional de Enfermedades Neoplásicas en el control del cáncer en el Perú MR Salazar, R Regalado-Rafael, JM Navarro, DM Montanez, ... Revista peruana de medicina experimental y salud pública 30, 105-112, 2013 | 113 | 2013 |
| Cost-effectiveness analysis of breast cancer control interventions in Peru SG Zelle, T Vidaurre, JE Abugattas, JE Manrique, G Sarria, J Jeronimo, ... PloS one 8 (12), e82575, 2013 | 65 | 2013 |
| Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy CA Castaneda, E Mittendorf, S Casavilca, Y Wu, M Castillo, P Arboleda, ... World journal of clinical oncology 7 (5), 387, 2016 | 60 | 2016 |
| A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor … RW Carlson, A O’Neill, T Vidaurre, HL Gomez, SS Badve, GW Sledge Breast cancer research and treatment 133, 1049-1056, 2012 | 51 | 2012 |
| Mamografía como instrumento de tamizaje en cáncer de mama J Abugattas Saba, J Manrique Hinojosa, T Vidaurre Rojas Revista Peruana de Ginecología y Obstetricia 61 (3), 311-319, 2015 | 49 | 2015 |
| Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1, CLIP4 and MSC DNA methylation in endoscopic biopsies F Pirini, S Noazin, MH Jahuira-Arias, S Rodriguez-Torres, L Friess, ... Oncotarget 8 (24), 38501, 2017 | 48 | 2017 |
| The implementation of the Plan Esperanza and response to the imPACT Review T Vidaurre, C Santos, H Gómez, G Sarria, E Amorin, M López, ... The Lancet Oncology 18 (10), e595-e606, 2017 | 47 | 2017 |
| A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease JA Pinto, J Araujo, NK Cardenas, Z Morante, F Doimi, T Vidaurre, ... NPJ genomic medicine 1 (1), 1-7, 2016 | 41 | 2016 |
| Human epidermal growth factor receptor 2–positive breast cancer is associated with indigenous American ancestry in Latin American women KM Marker, VA Zavala, T Vidaurre, PC Lott, JN Vásquez, ... Cancer research 80 (9), 1893-1901, 2020 | 31 | 2020 |
| Acelerando la innovación en el control del cáncer en el Perú C Santos-Ortiz, J Manrique, E Amorín, G Sarria, M Salazar, A Limache, ... Revista Peruana de Medicina Experimental y Salud Pública 33, 535-539, 2016 | 29 | 2016 |
| PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers CA Castaneda, M Lopez-Ilasaca, JA Pinto, M Chirinos-Arias, F Doimi, ... Hematology/oncology and stem cell therapy 7 (4), 142-148, 2014 | 28 | 2014 |
| Perspectives on strengthening cancer research and control in Latin America through partnerships and diplomacy: experience of the national cancer institute’s center for global … S Frech, CA Muha, LM Stevens, EL Trimble, R Brew, DP Perin, S Luciani, ... Journal of Global Oncology 4, 1-11, 2018 | 26 | 2018 |
| Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development T Vidaurre, J Wilkerson, R Simon, SE Bates, T Fojo The Cancer Journal 15 (5), 366-373, 2009 | 26 | 2009 |
| The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer D Cibula, L Dostálek, J Jarkovsky, CH Mom, A Lopez, H Falconer, ... European journal of cancer 158, 111-122, 2021 | 24 | 2021 |
| Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients HL Gómez, CA Castañeda, CE Vigil, T Vidaurre, RG Velarde, WR Cruz, ... Hematology/oncology and stem cell therapy 3 (3), 109-115, 2010 | 24 | 2010 |
